nodes	percent_of_prediction	percent_of_DWPC	metapath
Rimonabant—CYP1A2—Clobetasol propionate—psoriasis	0.141	0.196	CbGbCtD
Rimonabant—CYP1A2—Methoxsalen—psoriasis	0.0738	0.103	CbGbCtD
Rimonabant—CYP2D6—Hydroxyurea—psoriasis	0.0665	0.0928	CbGbCtD
Rimonabant—CYP3A4—Calcitriol—psoriasis	0.0497	0.0694	CbGbCtD
Rimonabant—CYP2C9—Cholecalciferol—psoriasis	0.0441	0.0615	CbGbCtD
Rimonabant—CYP2D6—Cholecalciferol—psoriasis	0.0403	0.0562	CbGbCtD
Rimonabant—CYP3A4—Methoxsalen—psoriasis	0.0387	0.0539	CbGbCtD
Rimonabant—CYP2C9—Cyclosporine—psoriasis	0.0289	0.0404	CbGbCtD
Rimonabant—CYP2D6—Cyclosporine—psoriasis	0.0265	0.0369	CbGbCtD
Rimonabant—CYP3A4—Cholecalciferol—psoriasis	0.0256	0.0357	CbGbCtD
Rimonabant—CYP3A4—Mycophenolate mofetil—psoriasis	0.0222	0.031	CbGbCtD
Rimonabant—CYP3A4—Triamcinolone—psoriasis	0.0222	0.031	CbGbCtD
Rimonabant—CYP2C9—Dexamethasone—psoriasis	0.0191	0.0266	CbGbCtD
Rimonabant—CYP3A4—Betamethasone—psoriasis	0.0191	0.0266	CbGbCtD
Rimonabant—CYP3A4—Prednisolone—psoriasis	0.0188	0.0262	CbGbCtD
Rimonabant—CYP3A4—Hydrocortisone—psoriasis	0.0178	0.0249	CbGbCtD
Rimonabant—CYP3A4—Prednisone—psoriasis	0.0178	0.0248	CbGbCtD
Rimonabant—CYP2D6—Dexamethasone—psoriasis	0.0174	0.0243	CbGbCtD
Rimonabant—CYP3A4—Cyclosporine—psoriasis	0.0168	0.0235	CbGbCtD
Rimonabant—CYP3A4—Dexamethasone—psoriasis	0.0111	0.0155	CbGbCtD
Rimonabant—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00202	0.0536	CbGpPWpGaD
Rimonabant—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.002	0.0531	CbGpPWpGaD
Rimonabant—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00188	0.05	CbGpPWpGaD
Rimonabant—CNR2—G alpha (i) signalling events—HCAR2—psoriasis	0.00151	0.04	CbGpPWpGaD
Rimonabant—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00125	0.0332	CbGpPWpGaD
Rimonabant—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00124	0.0329	CbGpPWpGaD
Rimonabant—CNR2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.0012	0.0318	CbGpPWpGaD
Rimonabant—CNR1—G alpha (i) signalling events—HCAR2—psoriasis	0.00118	0.0314	CbGpPWpGaD
Rimonabant—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.00106	0.0281	CbGpPWpGaD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00094	0.025	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—HCAR2—psoriasis	0.000912	0.0242	CbGpPWpGaD
Rimonabant—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000818	0.0217	CbGpPWpGaD
Rimonabant—CNR2—G alpha (i) signalling events—CCL20—psoriasis	0.000782	0.0208	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—HCAR2—psoriasis	0.000716	0.019	CbGpPWpGaD
Rimonabant—CNR2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000622	0.0165	CbGpPWpGaD
Rimonabant—CNR1—G alpha (i) signalling events—CCL20—psoriasis	0.000614	0.0163	CbGpPWpGaD
Rimonabant—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000519	0.0138	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—HCAR2—psoriasis	0.000515	0.0137	CbGpPWpGaD
Rimonabant—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000515	0.0137	CbGpPWpGaD
Rimonabant—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000513	0.0136	CbGpPWpGaD
Rimonabant—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000508	0.0135	CbGpPWpGaD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000488	0.013	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—CCL20—psoriasis	0.000474	0.0126	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—HCAR2—psoriasis	0.000468	0.0124	CbGpPWpGaD
Rimonabant—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00044	0.0117	CbGpPWpGaD
Rimonabant—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000434	0.0115	CbGpPWpGaD
Rimonabant—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000421	0.0112	CbGpPWpGaD
Rimonabant—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000417	0.0111	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—HCAR2—psoriasis	0.000404	0.0107	CbGpPWpGaD
Rimonabant—Rash—Acitretin—psoriasis	0.000393	0.0016	CcSEcCtD
Rimonabant—Dermatitis—Acitretin—psoriasis	0.000392	0.0016	CcSEcCtD
Rimonabant—Rash—Fluocinolone Acetonide—psoriasis	0.000392	0.0016	CcSEcCtD
Rimonabant—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000391	0.00159	CcSEcCtD
Rimonabant—Anorexia—Mycophenolic acid—psoriasis	0.00039	0.00159	CcSEcCtD
Rimonabant—Muscle spasms—Cyclosporine—psoriasis	0.00039	0.00159	CcSEcCtD
Rimonabant—Headache—Acitretin—psoriasis	0.00039	0.00159	CcSEcCtD
Rimonabant—Headache—Fluocinolone Acetonide—psoriasis	0.000389	0.00159	CcSEcCtD
Rimonabant—Tension—Mycophenolate mofetil—psoriasis	0.000389	0.00158	CcSEcCtD
Rimonabant—Nervousness—Mycophenolate mofetil—psoriasis	0.000385	0.00157	CcSEcCtD
Rimonabant—Muscle spasms—Mycophenolate mofetil—psoriasis	0.000381	0.00155	CcSEcCtD
Rimonabant—Tremor—Cyclosporine—psoriasis	0.00038	0.00155	CcSEcCtD
Rimonabant—Lethargy—Methotrexate—psoriasis	0.00038	0.00155	CcSEcCtD
Rimonabant—CNR1—GPCR ligand binding—CCL20—psoriasis	0.000372	0.00987	CbGpPWpGaD
Rimonabant—Tremor—Mycophenolate mofetil—psoriasis	0.000371	0.00151	CcSEcCtD
Rimonabant—Insomnia—Mycophenolic acid—psoriasis	0.00037	0.00151	CcSEcCtD
Rimonabant—Nausea—Acitretin—psoriasis	0.00037	0.00151	CcSEcCtD
Rimonabant—Nausea—Fluocinolone Acetonide—psoriasis	0.000369	0.0015	CcSEcCtD
Rimonabant—Paraesthesia—Mycophenolic acid—psoriasis	0.000368	0.0015	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—HCAR2—psoriasis	0.000367	0.00975	CbGpPWpGaD
Rimonabant—Mental disorder—Hydrocortisone—psoriasis	0.000363	0.00148	CcSEcCtD
Rimonabant—Malnutrition—Hydrocortisone—psoriasis	0.000361	0.00147	CcSEcCtD
Rimonabant—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000357	0.00947	CbGpPWpGaD
Rimonabant—Decreased appetite—Mycophenolic acid—psoriasis	0.000356	0.00145	CcSEcCtD
Rimonabant—Irritability—Methotrexate—psoriasis	0.000356	0.00145	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000354	0.00144	CcSEcCtD
Rimonabant—Fatigue—Mycophenolic acid—psoriasis	0.000353	0.00144	CcSEcCtD
Rimonabant—Mood swings—Methotrexate—psoriasis	0.000353	0.00144	CcSEcCtD
Rimonabant—Hallucination—Betamethasone—psoriasis	0.000352	0.00144	CcSEcCtD
Rimonabant—Hallucination—Dexamethasone—psoriasis	0.000352	0.00144	CcSEcCtD
Rimonabant—Convulsion—Cyclosporine—psoriasis	0.000352	0.00143	CcSEcCtD
Rimonabant—Asthenia—Hydroxyurea—psoriasis	0.000351	0.00143	CcSEcCtD
Rimonabant—Anxiety—Cyclosporine—psoriasis	0.000344	0.0014	CcSEcCtD
Rimonabant—CNR1—BDNF signaling pathway—NFKBIA—psoriasis	0.000344	0.00914	CbGpPWpGaD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000343	0.0014	CcSEcCtD
Rimonabant—Convulsion—Mycophenolate mofetil—psoriasis	0.000343	0.0014	CcSEcCtD
Rimonabant—Depression—Prednisone—psoriasis	0.000343	0.0014	CcSEcCtD
Rimonabant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00034	0.00902	CbGpPWpGaD
Rimonabant—Dry mouth—Cyclosporine—psoriasis	0.000338	0.00138	CcSEcCtD
Rimonabant—Anxiety—Mycophenolate mofetil—psoriasis	0.000336	0.00137	CcSEcCtD
Rimonabant—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000335	0.0089	CbGpPWpGaD
Rimonabant—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000335	0.00136	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000335	0.00136	CcSEcCtD
Rimonabant—Diarrhoea—Hydroxyurea—psoriasis	0.000335	0.00136	CcSEcCtD
Rimonabant—Dry mouth—Mycophenolate mofetil—psoriasis	0.00033	0.00134	CcSEcCtD
Rimonabant—Infection—Cyclosporine—psoriasis	0.000329	0.00134	CcSEcCtD
Rimonabant—Nervous system disorder—Cyclosporine—psoriasis	0.000325	0.00132	CcSEcCtD
Rimonabant—Abdominal pain—Mycophenolic acid—psoriasis	0.000324	0.00132	CcSEcCtD
Rimonabant—Dizziness—Hydroxyurea—psoriasis	0.000323	0.00132	CcSEcCtD
Rimonabant—Skin disorder—Cyclosporine—psoriasis	0.000322	0.00131	CcSEcCtD
Rimonabant—Angiopathy—Betamethasone—psoriasis	0.000321	0.00131	CcSEcCtD
Rimonabant—Angiopathy—Dexamethasone—psoriasis	0.000321	0.00131	CcSEcCtD
Rimonabant—Infection—Mycophenolate mofetil—psoriasis	0.000321	0.00131	CcSEcCtD
Rimonabant—Hyperhidrosis—Cyclosporine—psoriasis	0.00032	0.0013	CcSEcCtD
Rimonabant—Convulsion—Prednisolone—psoriasis	0.00032	0.0013	CcSEcCtD
Rimonabant—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000317	0.00129	CcSEcCtD
Rimonabant—Anorexia—Cyclosporine—psoriasis	0.000316	0.00129	CcSEcCtD
Rimonabant—Skin disorder—Mycophenolate mofetil—psoriasis	0.000314	0.00128	CcSEcCtD
Rimonabant—Convulsion—Hydrocortisone—psoriasis	0.000313	0.00127	CcSEcCtD
Rimonabant—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000312	0.00127	CcSEcCtD
Rimonabant—Vomiting—Hydroxyurea—psoriasis	0.000311	0.00127	CcSEcCtD
Rimonabant—Abdominal discomfort—Methotrexate—psoriasis	0.000309	0.00126	CcSEcCtD
Rimonabant—Rash—Hydroxyurea—psoriasis	0.000308	0.00126	CcSEcCtD
Rimonabant—Anorexia—Mycophenolate mofetil—psoriasis	0.000308	0.00126	CcSEcCtD
Rimonabant—Dermatitis—Hydroxyurea—psoriasis	0.000308	0.00125	CcSEcCtD
Rimonabant—Hallucination—Prednisone—psoriasis	0.000307	0.00125	CcSEcCtD
Rimonabant—Headache—Hydroxyurea—psoriasis	0.000306	0.00125	CcSEcCtD
Rimonabant—Anxiety—Hydrocortisone—psoriasis	0.000306	0.00125	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000305	0.00124	CcSEcCtD
Rimonabant—Connective tissue disorder—Prednisone—psoriasis	0.000303	0.00123	CcSEcCtD
Rimonabant—Insomnia—Cyclosporine—psoriasis	0.0003	0.00122	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Methotrexate—psoriasis	0.000299	0.00122	CcSEcCtD
Rimonabant—Paraesthesia—Cyclosporine—psoriasis	0.000298	0.00121	CcSEcCtD
Rimonabant—Convulsion—Triamcinolone—psoriasis	0.000294	0.0012	CcSEcCtD
Rimonabant—Asthenia—Mycophenolic acid—psoriasis	0.000294	0.0012	CcSEcCtD
Rimonabant—Infection—Hydrocortisone—psoriasis	0.000293	0.00119	CcSEcCtD
Rimonabant—Insomnia—Mycophenolate mofetil—psoriasis	0.000292	0.00119	CcSEcCtD
Rimonabant—Hyperhidrosis—Prednisolone—psoriasis	0.000291	0.00119	CcSEcCtD
Rimonabant—Nausea—Hydroxyurea—psoriasis	0.00029	0.00118	CcSEcCtD
Rimonabant—Paraesthesia—Mycophenolate mofetil—psoriasis	0.00029	0.00118	CcSEcCtD
Rimonabant—Pruritus—Mycophenolic acid—psoriasis	0.00029	0.00118	CcSEcCtD
Rimonabant—Nervous system disorder—Hydrocortisone—psoriasis	0.000289	0.00118	CcSEcCtD
Rimonabant—Decreased appetite—Cyclosporine—psoriasis	0.000288	0.00117	CcSEcCtD
Rimonabant—Infestation NOS—Methotrexate—psoriasis	0.000287	0.00117	CcSEcCtD
Rimonabant—Infestation—Methotrexate—psoriasis	0.000287	0.00117	CcSEcCtD
Rimonabant—Depression—Methotrexate—psoriasis	0.000286	0.00117	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000286	0.00117	CcSEcCtD
Rimonabant—Skin disorder—Hydrocortisone—psoriasis	0.000286	0.00117	CcSEcCtD
Rimonabant—Fatigue—Cyclosporine—psoriasis	0.000286	0.00116	CcSEcCtD
Rimonabant—Hyperhidrosis—Hydrocortisone—psoriasis	0.000285	0.00116	CcSEcCtD
Rimonabant—Dry mouth—Triamcinolone—psoriasis	0.000283	0.00115	CcSEcCtD
Rimonabant—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000281	0.00114	CcSEcCtD
Rimonabant—Anorexia—Hydrocortisone—psoriasis	0.000281	0.00114	CcSEcCtD
Rimonabant—Diarrhoea—Mycophenolic acid—psoriasis	0.00028	0.00114	CcSEcCtD
Rimonabant—Angiopathy—Prednisone—psoriasis	0.00028	0.00114	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000279	0.00114	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—HCAR2—psoriasis	0.000276	0.00734	CbGpPWpGaD
Rimonabant—Infection—Triamcinolone—psoriasis	0.000275	0.00112	CcSEcCtD
Rimonabant—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000275	0.00731	CbGpPWpGaD
Rimonabant—Insomnia—Prednisolone—psoriasis	0.000273	0.00111	CcSEcCtD
Rimonabant—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000272	0.00721	CbGpPWpGaD
Rimonabant—Gastrointestinal pain—Cyclosporine—psoriasis	0.000271	0.0011	CcSEcCtD
Rimonabant—Dizziness—Mycophenolic acid—psoriasis	0.000271	0.0011	CcSEcCtD
Rimonabant—Paraesthesia—Prednisolone—psoriasis	0.000271	0.0011	CcSEcCtD
Rimonabant—Mental disorder—Prednisone—psoriasis	0.00027	0.0011	CcSEcCtD
Rimonabant—Malnutrition—Prednisone—psoriasis	0.000268	0.00109	CcSEcCtD
Rimonabant—Hyperhidrosis—Triamcinolone—psoriasis	0.000268	0.00109	CcSEcCtD
Rimonabant—CNR2—GPCR downstream signaling—CCL20—psoriasis	0.000268	0.00711	CbGpPWpGaD
Rimonabant—Convulsion—Betamethasone—psoriasis	0.000267	0.00109	CcSEcCtD
Rimonabant—Convulsion—Dexamethasone—psoriasis	0.000267	0.00109	CcSEcCtD
Rimonabant—Insomnia—Hydrocortisone—psoriasis	0.000266	0.00108	CcSEcCtD
Rimonabant—Paraesthesia—Hydrocortisone—psoriasis	0.000264	0.00108	CcSEcCtD
Rimonabant—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000264	0.00108	CcSEcCtD
Rimonabant—Abdominal pain—Cyclosporine—psoriasis	0.000262	0.00107	CcSEcCtD
Rimonabant—Anxiety—Betamethasone—psoriasis	0.000262	0.00107	CcSEcCtD
Rimonabant—Anxiety—Dexamethasone—psoriasis	0.000262	0.00107	CcSEcCtD
Rimonabant—Vomiting—Mycophenolic acid—psoriasis	0.00026	0.00106	CcSEcCtD
Rimonabant—Rash—Mycophenolic acid—psoriasis	0.000258	0.00105	CcSEcCtD
Rimonabant—Dermatitis—Mycophenolic acid—psoriasis	0.000258	0.00105	CcSEcCtD
Rimonabant—Headache—Mycophenolic acid—psoriasis	0.000257	0.00105	CcSEcCtD
Rimonabant—Decreased appetite—Hydrocortisone—psoriasis	0.000256	0.00104	CcSEcCtD
Rimonabant—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000256	0.00104	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000254	0.00104	CcSEcCtD
Rimonabant—Fatigue—Hydrocortisone—psoriasis	0.000254	0.00103	CcSEcCtD
Rimonabant—Insomnia—Triamcinolone—psoriasis	0.000251	0.00102	CcSEcCtD
Rimonabant—Infection—Dexamethasone—psoriasis	0.00025	0.00102	CcSEcCtD
Rimonabant—Infection—Betamethasone—psoriasis	0.00025	0.00102	CcSEcCtD
Rimonabant—Paraesthesia—Triamcinolone—psoriasis	0.000249	0.00101	CcSEcCtD
Rimonabant—Nervous system disorder—Betamethasone—psoriasis	0.000247	0.00101	CcSEcCtD
Rimonabant—Nervous system disorder—Dexamethasone—psoriasis	0.000247	0.00101	CcSEcCtD
Rimonabant—Nausea—Mycophenolic acid—psoriasis	0.000243	0.000991	CcSEcCtD
Rimonabant—Hyperhidrosis—Dexamethasone—psoriasis	0.000243	0.000991	CcSEcCtD
Rimonabant—Hyperhidrosis—Betamethasone—psoriasis	0.000243	0.000991	CcSEcCtD
Rimonabant—CNR2—Signaling by GPCR—CCL20—psoriasis	0.000243	0.00646	CbGpPWpGaD
Rimonabant—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000241	0.000981	CcSEcCtD
Rimonabant—Anorexia—Betamethasone—psoriasis	0.00024	0.000977	CcSEcCtD
Rimonabant—Anorexia—Dexamethasone—psoriasis	0.00024	0.000977	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—TAGAP—psoriasis	0.00024	0.00637	CbGpPWpGaD
Rimonabant—Fatigue—Triamcinolone—psoriasis	0.000239	0.000974	CcSEcCtD
Rimonabant—Asthenia—Cyclosporine—psoriasis	0.000238	0.000968	CcSEcCtD
Rimonabant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000236	0.00628	CbGpPWpGaD
Rimonabant—Pruritus—Cyclosporine—psoriasis	0.000234	0.000955	CcSEcCtD
Rimonabant—Angiopathy—Methotrexate—psoriasis	0.000234	0.000953	CcSEcCtD
Rimonabant—Abdominal pain—Hydrocortisone—psoriasis	0.000233	0.000948	CcSEcCtD
Rimonabant—Convulsion—Prednisone—psoriasis	0.000233	0.000948	CcSEcCtD
Rimonabant—Mediastinal disorder—Methotrexate—psoriasis	0.000232	0.000946	CcSEcCtD
Rimonabant—Asthenia—Mycophenolate mofetil—psoriasis	0.000232	0.000945	CcSEcCtD
Rimonabant—Pruritus—Mycophenolate mofetil—psoriasis	0.000229	0.000932	CcSEcCtD
Rimonabant—CNR1—BDNF signaling pathway—JUN—psoriasis	0.000228	0.00606	CbGpPWpGaD
Rimonabant—Anxiety—Prednisone—psoriasis	0.000228	0.000928	CcSEcCtD
Rimonabant—Insomnia—Dexamethasone—psoriasis	0.000228	0.000927	CcSEcCtD
Rimonabant—Insomnia—Betamethasone—psoriasis	0.000228	0.000927	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000227	0.000925	CcSEcCtD
Rimonabant—Diarrhoea—Cyclosporine—psoriasis	0.000227	0.000924	CcSEcCtD
Rimonabant—Paraesthesia—Dexamethasone—psoriasis	0.000226	0.00092	CcSEcCtD
Rimonabant—Paraesthesia—Betamethasone—psoriasis	0.000226	0.00092	CcSEcCtD
Rimonabant—Mental disorder—Methotrexate—psoriasis	0.000226	0.00092	CcSEcCtD
Rimonabant—Malnutrition—Methotrexate—psoriasis	0.000224	0.000914	CcSEcCtD
Rimonabant—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000224	0.00594	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000222	0.00589	CbGpPWpGaD
Rimonabant—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000221	0.000901	CcSEcCtD
Rimonabant—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000221	0.00586	CbGpPWpGaD
Rimonabant—CNR1—BDNF signaling pathway—NFKB1—psoriasis	0.00022	0.00583	CbGpPWpGaD
Rimonabant—Dizziness—Cyclosporine—psoriasis	0.000219	0.000893	CcSEcCtD
Rimonabant—Decreased appetite—Dexamethasone—psoriasis	0.000219	0.000891	CcSEcCtD
Rimonabant—Decreased appetite—Betamethasone—psoriasis	0.000219	0.000891	CcSEcCtD
Rimonabant—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000219	0.00581	CbGpPWpGaD
Rimonabant—Infection—Prednisone—psoriasis	0.000218	0.000887	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Betamethasone—psoriasis	0.000217	0.000885	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000217	0.000885	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—HCAR2—psoriasis	0.000217	0.00576	CbGpPWpGaD
Rimonabant—Fatigue—Dexamethasone—psoriasis	0.000217	0.000884	CcSEcCtD
Rimonabant—Fatigue—Betamethasone—psoriasis	0.000217	0.000884	CcSEcCtD
Rimonabant—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000217	0.00576	CbGpPWpGaD
Rimonabant—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000216	0.00573	CbGpPWpGaD
Rimonabant—Nervous system disorder—Prednisone—psoriasis	0.000215	0.000875	CcSEcCtD
Rimonabant—Dizziness—Mycophenolate mofetil—psoriasis	0.000214	0.000871	CcSEcCtD
Rimonabant—Skin disorder—Prednisone—psoriasis	0.000213	0.000867	CcSEcCtD
Rimonabant—Hyperhidrosis—Prednisone—psoriasis	0.000212	0.000863	CcSEcCtD
Rimonabant—Asthenia—Hydrocortisone—psoriasis	0.000211	0.000861	CcSEcCtD
Rimonabant—CNR2—G alpha (i) signalling events—CXCL8—psoriasis	0.000211	0.00561	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000211	0.00561	CbGpPWpGaD
Rimonabant—Vomiting—Cyclosporine—psoriasis	0.000211	0.000858	CcSEcCtD
Rimonabant—CNR1—GPCR downstream signaling—CCL20—psoriasis	0.00021	0.00558	CbGpPWpGaD
Rimonabant—Rash—Cyclosporine—psoriasis	0.000209	0.000851	CcSEcCtD
Rimonabant—Anorexia—Prednisone—psoriasis	0.000209	0.000851	CcSEcCtD
Rimonabant—Dermatitis—Cyclosporine—psoriasis	0.000209	0.00085	CcSEcCtD
Rimonabant—Pruritus—Hydrocortisone—psoriasis	0.000208	0.000849	CcSEcCtD
Rimonabant—Headache—Cyclosporine—psoriasis	0.000208	0.000846	CcSEcCtD
Rimonabant—Gastrointestinal pain—Betamethasone—psoriasis	0.000206	0.000838	CcSEcCtD
Rimonabant—Gastrointestinal pain—Dexamethasone—psoriasis	0.000206	0.000838	CcSEcCtD
Rimonabant—Vomiting—Mycophenolate mofetil—psoriasis	0.000206	0.000837	CcSEcCtD
Rimonabant—Rash—Mycophenolate mofetil—psoriasis	0.000204	0.00083	CcSEcCtD
Rimonabant—Dermatitis—Mycophenolate mofetil—psoriasis	0.000204	0.000829	CcSEcCtD
Rimonabant—Headache—Mycophenolate mofetil—psoriasis	0.000203	0.000825	CcSEcCtD
Rimonabant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000202	0.00537	CbGpPWpGaD
Rimonabant—Diarrhoea—Hydrocortisone—psoriasis	0.000201	0.000821	CcSEcCtD
Rimonabant—Dizziness—Prednisolone—psoriasis	0.000199	0.000812	CcSEcCtD
Rimonabant—Asthenia—Triamcinolone—psoriasis	0.000199	0.00081	CcSEcCtD
Rimonabant—Abdominal pain—Betamethasone—psoriasis	0.000199	0.00081	CcSEcCtD
Rimonabant—Abdominal pain—Dexamethasone—psoriasis	0.000199	0.00081	CcSEcCtD
Rimonabant—Insomnia—Prednisone—psoriasis	0.000198	0.000807	CcSEcCtD
Rimonabant—CNR1—BDNF signaling pathway—STAT3—psoriasis	0.000197	0.00524	CbGpPWpGaD
Rimonabant—Nausea—Cyclosporine—psoriasis	0.000197	0.000802	CcSEcCtD
Rimonabant—Paraesthesia—Prednisone—psoriasis	0.000197	0.000801	CcSEcCtD
Rimonabant—Pruritus—Triamcinolone—psoriasis	0.000196	0.000799	CcSEcCtD
Rimonabant—Dizziness—Hydrocortisone—psoriasis	0.000195	0.000793	CcSEcCtD
Rimonabant—Convulsion—Methotrexate—psoriasis	0.000194	0.000792	CcSEcCtD
Rimonabant—Nausea—Mycophenolate mofetil—psoriasis	0.000192	0.000782	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—CCL20—psoriasis	0.000191	0.00507	CbGpPWpGaD
Rimonabant—Decreased appetite—Prednisone—psoriasis	0.00019	0.000776	CcSEcCtD
Rimonabant—Rash—Prednisolone—psoriasis	0.00019	0.000774	CcSEcCtD
Rimonabant—Dermatitis—Prednisolone—psoriasis	0.00019	0.000774	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00019	0.000773	CcSEcCtD
Rimonabant—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000189	0.00503	CbGpPWpGaD
Rimonabant—Fatigue—Prednisone—psoriasis	0.000189	0.000769	CcSEcCtD
Rimonabant—Headache—Prednisolone—psoriasis	0.000189	0.000769	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—TAGAP—psoriasis	0.000188	0.005	CbGpPWpGaD
Rimonabant—Vomiting—Hydrocortisone—psoriasis	0.000187	0.000763	CcSEcCtD
Rimonabant—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000187	0.00496	CbGpPWpGaD
Rimonabant—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000187	0.00495	CbGpPWpGaD
Rimonabant—Rash—Hydrocortisone—psoriasis	0.000186	0.000756	CcSEcCtD
Rimonabant—Dermatitis—Hydrocortisone—psoriasis	0.000186	0.000756	CcSEcCtD
Rimonabant—Headache—Hydrocortisone—psoriasis	0.000184	0.000751	CcSEcCtD
Rimonabant—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000184	0.00488	CbGpPWpGaD
Rimonabant—Dizziness—Triamcinolone—psoriasis	0.000183	0.000747	CcSEcCtD
Rimonabant—Infection—Methotrexate—psoriasis	0.000182	0.000741	CcSEcCtD
Rimonabant—Asthenia—Dexamethasone—psoriasis	0.000181	0.000735	CcSEcCtD
Rimonabant—Asthenia—Betamethasone—psoriasis	0.000181	0.000735	CcSEcCtD
Rimonabant—Nervous system disorder—Methotrexate—psoriasis	0.00018	0.000731	CcSEcCtD
Rimonabant—Gastrointestinal pain—Prednisone—psoriasis	0.000179	0.00073	CcSEcCtD
Rimonabant—Nausea—Prednisolone—psoriasis	0.000179	0.00073	CcSEcCtD
Rimonabant—Pruritus—Dexamethasone—psoriasis	0.000178	0.000725	CcSEcCtD
Rimonabant—Pruritus—Betamethasone—psoriasis	0.000178	0.000725	CcSEcCtD
Rimonabant—Skin disorder—Methotrexate—psoriasis	0.000178	0.000725	CcSEcCtD
Rimonabant—Hyperhidrosis—Methotrexate—psoriasis	0.000177	0.000721	CcSEcCtD
Rimonabant—Vomiting—Triamcinolone—psoriasis	0.000176	0.000718	CcSEcCtD
Rimonabant—Nausea—Hydrocortisone—psoriasis	0.000175	0.000713	CcSEcCtD
Rimonabant—Rash—Triamcinolone—psoriasis	0.000175	0.000712	CcSEcCtD
Rimonabant—Dermatitis—Triamcinolone—psoriasis	0.000175	0.000712	CcSEcCtD
Rimonabant—Anorexia—Methotrexate—psoriasis	0.000175	0.000711	CcSEcCtD
Rimonabant—Headache—Triamcinolone—psoriasis	0.000174	0.000708	CcSEcCtD
Rimonabant—Abdominal pain—Prednisone—psoriasis	0.000173	0.000706	CcSEcCtD
Rimonabant—Diarrhoea—Betamethasone—psoriasis	0.000172	0.000701	CcSEcCtD
Rimonabant—Diarrhoea—Dexamethasone—psoriasis	0.000172	0.000701	CcSEcCtD
Rimonabant—CNR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000168	0.00446	CbGpPWpGaD
Rimonabant—Dizziness—Dexamethasone—psoriasis	0.000166	0.000678	CcSEcCtD
Rimonabant—Dizziness—Betamethasone—psoriasis	0.000166	0.000678	CcSEcCtD
Rimonabant—CNR1—G alpha (i) signalling events—CXCL8—psoriasis	0.000166	0.0044	CbGpPWpGaD
Rimonabant—Insomnia—Methotrexate—psoriasis	0.000166	0.000675	CcSEcCtD
Rimonabant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000165	0.00438	CbGpPWpGaD
Rimonabant—Nausea—Triamcinolone—psoriasis	0.000165	0.000671	CcSEcCtD
Rimonabant—Paraesthesia—Methotrexate—psoriasis	0.000164	0.00067	CcSEcCtD
Rimonabant—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000163	0.00434	CbGpPWpGaD
Rimonabant—Vomiting—Dexamethasone—psoriasis	0.00016	0.000652	CcSEcCtD
Rimonabant—Vomiting—Betamethasone—psoriasis	0.00016	0.000652	CcSEcCtD
Rimonabant—Decreased appetite—Methotrexate—psoriasis	0.000159	0.000648	CcSEcCtD
Rimonabant—Rash—Betamethasone—psoriasis	0.000159	0.000646	CcSEcCtD
Rimonabant—Rash—Dexamethasone—psoriasis	0.000159	0.000646	CcSEcCtD
Rimonabant—Dermatitis—Betamethasone—psoriasis	0.000158	0.000646	CcSEcCtD
Rimonabant—Dermatitis—Dexamethasone—psoriasis	0.000158	0.000646	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Methotrexate—psoriasis	0.000158	0.000644	CcSEcCtD
Rimonabant—Fatigue—Methotrexate—psoriasis	0.000158	0.000643	CcSEcCtD
Rimonabant—Headache—Betamethasone—psoriasis	0.000158	0.000642	CcSEcCtD
Rimonabant—Headache—Dexamethasone—psoriasis	0.000158	0.000642	CcSEcCtD
Rimonabant—Asthenia—Prednisone—psoriasis	0.000157	0.00064	CcSEcCtD
Rimonabant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000156	0.00414	CbGpPWpGaD
Rimonabant—Pruritus—Prednisone—psoriasis	0.000155	0.000631	CcSEcCtD
Rimonabant—Diarrhoea—Prednisone—psoriasis	0.00015	0.000611	CcSEcCtD
Rimonabant—Gastrointestinal pain—Methotrexate—psoriasis	0.00015	0.00061	CcSEcCtD
Rimonabant—Nausea—Betamethasone—psoriasis	0.000149	0.000609	CcSEcCtD
Rimonabant—Nausea—Dexamethasone—psoriasis	0.000149	0.000609	CcSEcCtD
Rimonabant—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000146	0.00388	CbGpPWpGaD
Rimonabant—Dizziness—Prednisone—psoriasis	0.000145	0.00059	CcSEcCtD
Rimonabant—Abdominal pain—Methotrexate—psoriasis	0.000145	0.00059	CcSEcCtD
Rimonabant—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000144	0.00383	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CCL20—psoriasis	0.000144	0.00381	CbGpPWpGaD
Rimonabant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000141	0.00374	CbGpPWpGaD
Rimonabant—Vomiting—Prednisone—psoriasis	0.000139	0.000567	CcSEcCtD
Rimonabant—Rash—Prednisone—psoriasis	0.000138	0.000563	CcSEcCtD
Rimonabant—Dermatitis—Prednisone—psoriasis	0.000138	0.000562	CcSEcCtD
Rimonabant—Headache—Prednisone—psoriasis	0.000137	0.000559	CcSEcCtD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000132	0.0035	CbGpPWpGaD
Rimonabant—Asthenia—Methotrexate—psoriasis	0.000131	0.000535	CcSEcCtD
Rimonabant—Nausea—Prednisone—psoriasis	0.00013	0.00053	CcSEcCtD
Rimonabant—Pruritus—Methotrexate—psoriasis	0.00013	0.000528	CcSEcCtD
Rimonabant—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000129	0.00342	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—CXCL8—psoriasis	0.000128	0.0034	CbGpPWpGaD
Rimonabant—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000126	0.00335	CbGpPWpGaD
Rimonabant—Diarrhoea—Methotrexate—psoriasis	0.000125	0.00051	CcSEcCtD
Rimonabant—Dizziness—Methotrexate—psoriasis	0.000121	0.000493	CcSEcCtD
Rimonabant—Vomiting—Methotrexate—psoriasis	0.000116	0.000474	CcSEcCtD
Rimonabant—Rash—Methotrexate—psoriasis	0.000115	0.00047	CcSEcCtD
Rimonabant—Dermatitis—Methotrexate—psoriasis	0.000115	0.00047	CcSEcCtD
Rimonabant—Headache—Methotrexate—psoriasis	0.000115	0.000467	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—CCL20—psoriasis	0.000113	0.00299	CbGpPWpGaD
Rimonabant—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	0.000109	0.0029	CbGpPWpGaD
Rimonabant—Nausea—Methotrexate—psoriasis	0.000109	0.000443	CcSEcCtD
Rimonabant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000109	0.00289	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—CXCL8—psoriasis	0.0001	0.00267	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	9.08e-05	0.00241	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—SOCS1—psoriasis	7.91e-05	0.0021	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.85e-05	0.00208	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	7.55e-05	0.00201	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—TYK2—psoriasis	7.54e-05	0.002	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—CXCL8—psoriasis	7.23e-05	0.00192	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.86e-05	0.00182	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CXCL8—psoriasis	6.56e-05	0.00174	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—SOCS1—psoriasis	6.21e-05	0.00165	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—TYK2—psoriasis	5.92e-05	0.00157	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.88e-05	0.00156	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.88e-05	0.00156	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—LEP—psoriasis	5.84e-05	0.00155	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—APOE—psoriasis	5.84e-05	0.00155	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—CXCL8—psoriasis	5.67e-05	0.00151	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—NFKBIA—psoriasis	5.44e-05	0.00144	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CXCL8—psoriasis	5.15e-05	0.00137	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—LEP—psoriasis	4.58e-05	0.00122	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—APOE—psoriasis	4.58e-05	0.00122	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—NDUFA5—psoriasis	4.5e-05	0.00119	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—NDUFA5—psoriasis	4.46e-05	0.00118	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TYK2—psoriasis	4.45e-05	0.00118	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—NFKBIA—psoriasis	4.27e-05	0.00113	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.16e-05	0.0011	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CXCL8—psoriasis	3.88e-05	0.00103	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CYP2S1—psoriasis	3.82e-05	0.00102	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—NDUFA5—psoriasis	3.81e-05	0.00101	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CYP2S1—psoriasis	3.79e-05	0.00101	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—IL6—psoriasis	3.69e-05	0.000979	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—JUN—psoriasis	3.61e-05	0.000957	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.55e-05	0.000944	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TYK2—psoriasis	3.5e-05	0.000928	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—NFKB1—psoriasis	3.47e-05	0.000922	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CYP2S1—psoriasis	3.24e-05	0.000861	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—VEGFA—psoriasis	3.15e-05	0.000836	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—STAT3—psoriasis	3.12e-05	0.000828	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CXCL8—psoriasis	3.04e-05	0.000808	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—NDUFA5—psoriasis	2.94e-05	0.000781	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—IL6—psoriasis	2.89e-05	0.000769	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—JUN—psoriasis	2.83e-05	0.000751	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—NFKB1—psoriasis	2.72e-05	0.000723	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CYP2S1—psoriasis	2.5e-05	0.000664	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—VEGFA—psoriasis	2.47e-05	0.000656	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—STAT3—psoriasis	2.45e-05	0.00065	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TP53—psoriasis	2.38e-05	0.000632	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IL6—psoriasis	2.18e-05	0.000579	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.99e-05	0.000528	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CARM1—psoriasis	1.87e-05	0.000496	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TP53—psoriasis	1.87e-05	0.000496	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CARM1—psoriasis	1.85e-05	0.000492	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.73e-05	0.00046	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—IL6—psoriasis	1.71e-05	0.000454	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.7e-05	0.000451	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CARM1—psoriasis	1.58e-05	0.00042	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.48e-05	0.000393	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CARM1—psoriasis	1.22e-05	0.000324	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CAT—psoriasis	1.15e-05	0.000305	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CAT—psoriasis	1.14e-05	0.000302	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CAT—psoriasis	9.73e-06	0.000258	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—APOE—psoriasis	8.93e-06	0.000237	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—APOE—psoriasis	8.85e-06	0.000235	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PPARG—psoriasis	7.78e-06	0.000206	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PPARG—psoriasis	7.71e-06	0.000205	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—APOE—psoriasis	7.56e-06	0.000201	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CAT—psoriasis	7.51e-06	0.000199	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PPARG—psoriasis	6.59e-06	0.000175	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—APOE—psoriasis	5.84e-06	0.000155	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PPARG—psoriasis	5.08e-06	0.000135	CbGpPWpGaD
